Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Compounds related to curcumin receive U.S. patent

A U.S patent issued today to the University of Rochester and two other entities for the use of compounds related to a popular spice in the fight against cancer, acne, baldness, and other medical conditions.

13 Jun 2012

African-American survivors of prostate cancer have unmet psychosocial needs

Researchers at Moffitt Cancer Center have found that in African-American families where men are diagnosed with prostate cancer, they have unmet psychosocial needs that affect their survivorship, as well as family and social relationships.

12 Jun 2012

Piramal to present data on several molecular imaging compounds at SNM annual meeting

Piramal Imaging SA, a subsidiary of Piramal Healthcare Limited, will present data on several compounds from its molecular imaging portfolio at the Society of Nuclear Medicine's 59th annual meeting in Miami Beach, Fla., from June 9 - 13.

10 Jun 2012

Accuray announces outcome data from CyberKnife Prostate SBRT study

Accuray Incorporated, the premier radiation oncology company, announced today that outcome data on intermediate risk prostate cancer patients treated with CyberKnife Prostate SBRT was presented at the American Urological Association Meeting (AUA) 2012 held in Atlanta, Ga.

8 Jun 2012

Tp53 genetic mutation may play an important role in prostate cancer

A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.

8 Jun 2012

Artificial noses could allow quick disease screening and ultimately transform diagnostics

Artificial noses have, until now, been used to detect diseases such as urinary tract infection, Helicobacter pylori, tuberculosis, ear, nose and throat conditions and even lung cancer. They have also been clinically tested for use in continuous monitoring of different disease stages.

7 Jun 2012

Split-course RT valuable after hormone-resistant prostate cancer relapse

A split course of high-dose radiotherapy in men with progressive, hormone-refractory prostate cancer is effective and has an acceptable toxicity profile, report Australian researchers.

6 Jun 2012

Bayer announces updated data from radium-223 dichloride Phase III trial on CRPC

Bayer HealthCare today announced updated data from the pivotal Phase III ALSYMPCA (ALpharadin in SYMptomatic Prostate CAncer) trial for its investigational drug radium-223 dichloride in men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases.

6 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Ipsen, Active Biotech present OS data from tasquinimod Phase II study on CRPC at ASCO 2012

Active Biotech and Ipsen today presented overall survival (OS) data from the tasquinimod Phase II study in chemotherapy-naïve metastatic castrate resistant prostate cancer (CRPC) at the scientific conference "2012 ASCO Annual Meeting" held in Chicago (USA).

5 Jun 2012

Exelixis reports data from cabozantinib phase 3 trial on MTC

Exelixis, Inc. today reported data from the phase 3 pivotal trial of cabozantinib in patients with progressive, unresectable, locally advanced or metastatic medullary thyroid cancer (MTC).

5 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

Oncothyreon announces data from two clinical trials of PX-866 at ASCO meeting

Oncothyreon Inc. today announced that data from two clinical trials of PX-866, a pan-isoform phosphatidylinositol-3-kinase (PI-3K) inhibitor, were presented today at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

4 Jun 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Results from Janssen's ZYTIGA plus prednisone Phase 3 study on mCRPC

Results observed from pre-specified interim analyses of the randomized, placebo-controlled Phase 3 study, COU-AA-302, demonstrated that patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (ZYTIGA) plus prednisone showed a statistically significant improvement in radiographic progression-free survival (rPFS) and all secondary endpoints compared to patients treated with placebo plus prednisone.

4 Jun 2012

ZYTIGA Phase 3 study for metastatic prostate cancer presented at 48th ASCO

New data presented this weekend at the 48th annual meeting of the American Society of Clinical Oncology (ASCO) showed ZYTIGA (abiraterone acetate) may prove to be an important new treatment option for metastatic prostate cancer patients prior to receiving chemotherapy.

2 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Electronic nose and optoacoustics improve diagnosis of prostate cancer

Chances of survival of prostate cancer depend strongly on the stage at which the disease is diagnosed. Now scientists have developed new methods relying on an electronic nose and optoacoustics to improve the diagnosis techniques and avoid fatal treatment delays

2 Jun 2012